Heron Therapeutics Inc vs Nano Dimension Ltd - ADR — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M). The key difference: Nano Dimension Ltd - ADR is far larger — about 5.7× Heron Therapeutics Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | NNDM | |
|---|---|---|
Market Cap | $61.47M | $350.49M |
Sector | Health | Technology |
52-Week High | $1.49 | $2.14 |
52-Week Low | $0.32 | $1.21 |
Enterprise Value | $168.21M | -$54.35M |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
NNDM trades at $1.67, up 2.45% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $121 million with a net loss of $163 million, reflecting a negative net margin of -135.18%. Recent strategic actions include selling non-core assets to reduce cash burn and appointing an interim CEO amid board restructuring.
The outlook remains challenged by persistent losses and high cash burn, though asset sales may improve liquidity. Investment opportunity hinges on successful execution of cost-saving initiatives and strategic refocusing. Key risks include ongoing operational losses, leadership transitions, and competitive pressures in the additive manufacturing sector.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →